Related Experiment Videos
Aspects on reference values for tumor markers in human prostatic carcinoma.
P Ekman1, A Lewenhaupt, P Eneroth
1Department of Urology, Karolinska Hospital, Stockholm, Sweden.
American Journal of Clinical Oncology
|January 1, 1988
Summary
Elevated levels of prostate cancer markers like neopterin and osteocalcin indicate a worse prognosis. Adjusting cutoff levels higher than standard can improve prediction accuracy for cancer survival without increasing false negatives.
Area of Science:
- Oncology
- Biomarkers
- Prognostic Medicine
Background:
- Prostate cancer prognosis relies on accurate prediction of patient outcomes.
- Tumor markers are crucial for assessing disease progression and survival rates.
Purpose of the Study:
- To evaluate the prognostic efficiency of prostatic acid phosphatase (PAP), prostate-specific antigen (PSA), neopterin, and osteocalcin in newly diagnosed prostate cancer patients.
- To determine if adjusting standard cutoff levels for these markers improves their ability to predict cancer death and survival.
Main Methods:
- Analysis of a series of newly diagnosed prostate cancer patients.
- Testing the predictive capability of PAP, PSA, neopterin, and osteocalcin levels.
- Comparing prognostic efficiency at standard versus higher, adjusted cutoff levels.
Main Results:
- Elevated levels of all tested markers (neopterin, osteocalcin, PAP, PSA) indicated a worse prognosis.
- Increasing cutoff levels for neopterin and osteocalcin significantly improved survival prediction accuracy.
- Prostate-specific antigen (PSA) demonstrated high sensitivity but low specificity for prognosis.
Conclusions:
- Adjusting radioimmunoassay (RIA) kit-suggested cutoff levels for tumor markers can enhance prognostic efficiency in prostate cancer.
- Higher cutoff values for neopterin and osteocalcin improve prediction of short-term survival without increasing false negatives.
- Prostatic acid phosphatase (PAP) requires significantly higher cutoff levels for effective short-term prognosis prediction.